Chimeric Antigen Receptor (CAR) T-cell Therapy for Relapsed or Refractory Follicular Lymphoma

Clinical Trial Information

 

As of September 2020, there are two U.S.-based clinical trials evaluating chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory follicular lymphoma: ZUMA-5 and ELARA.

 
For more information on the ZUMA-5 clinical trial, tap here
For more information on the ELARA clinical trial, tap here 
ABOUT FIGURE 1
LEGAL
HOW  FIGURE 1 WORKS
PRESS